AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like These are the Top 5 Biotech Stocks (So Far) June 25, 2017 What You Need to Know About CARMA Therapeutics January 17, 2018 Roche's Star MS Drug Snags EU Approval January 11, 2018
